Searchable abstracts of presentations at key conferences in endocrinology

ea0038p198 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Vascular dysfunction in horses with insulin resistance

Morgan Ruth , Keen John , Walker Brian , Hadoke Patrick

Background: Vascular impairment, most commonly due to endothelial dysfunction, is associated with cardiovascular risk in humans with obesity, insulin resistance or Cushing’s syndrome. Similar endocrine disorders in horses, resulting in insulin resistance, are associated with laminitis, a dysfunction of the vasculature supplying the hooves, the mechanism of which is unclear. We hypothesised that horses with insulin resistance have both local and systemic evidence of vascul...

ea0034p208 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Abnormal glucocorticoid metabolism in horses with metabolic syndrome

Morgan Ruth , Hadoke Patrick , Walker Brian , Keen John

Activation of the hypothalamic–pituitary–adrenal (HPA) axis and altered tissue glucocorticoid action in obesity and metabolic syndrome has been attributed to altered peripheral cortisol metabolism. In human obesity, cortisol clearance is increased with up-regulation of A-ring reductases and down-regulation of cortisol-regenerating 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in liver, while in adipose tissue 11β-HSD1 is up-regulated. Rodent studi...

ea0077p174 | Metabolism, Obesity and Diabetes | SFEBES2021

Vitamin D status in horses and its association with adiposity

Dosi Miranda , Mellanby Richard , Hurst Emma , McGorum Bruce , Keen John , Morgan Ruth

Obesity and metabolic syndrome are highly prevalent in horses and ponies worldwide. Equine Metabolic Syndrome (EMS) shares much of the same pathophysiology with its human counterpart including adipose tissue dysfunction and insulin dysregulation. Vitamin D deficiency is strongly associated with obesity and insulin resistance in humans and supplementation is often recommended. In horses our understanding of vitamin D biology is limited and its association with EMS unknown. The ...

ea0050p005 | Adrenal and Steroids | SFEBES2017

20β-Dihydrocortisol; a weak endogenous agonist of the glucocorticoid receptor but a potent agonist of the mineralocorticoid receptor

Morgan Ruth , Beck Katharina , Nixon Mark , Homer Natalie , Melchers Diana , Houtman Rene , Meijer Onno , Hadoke Patrick , Odermatt Alex , Keen John , Walker Brian

Cortisol conversion to 20β-dihydrocortisol (20β-DHF) has been reported in many tissues and cells, including skin, muscle, thrombocytes and fibroblasts, although the enzyme responsible is poorly characterised. We have attributed 20β-DHF generation to carbonyl reductase 1 and shown increased activity of this pathway in adipose tissue in obesity in humans, horses and mice. This study addressed the hypothesis that 20β-DHF activates gl...

ea0050p005 | Adrenal and Steroids | SFEBES2017

20β-Dihydrocortisol; a weak endogenous agonist of the glucocorticoid receptor but a potent agonist of the mineralocorticoid receptor

Morgan Ruth , Beck Katharina , Nixon Mark , Homer Natalie , Melchers Diana , Houtman Rene , Meijer Onno , Hadoke Patrick , Odermatt Alex , Keen John , Walker Brian

Cortisol conversion to 20β-dihydrocortisol (20β-DHF) has been reported in many tissues and cells, including skin, muscle, thrombocytes and fibroblasts, although the enzyme responsible is poorly characterised. We have attributed 20β-DHF generation to carbonyl reductase 1 and shown increased activity of this pathway in adipose tissue in obesity in humans, horses and mice. This study addressed the hypothesis that 20β-DHF activates gl...